000286719 001__ 286719
000286719 005__ 20251001115227.0
000286719 0247_ $$2doi$$a10.1007/s11764-023-01507-w
000286719 0247_ $$2pmid$$apmid:38175366
000286719 0247_ $$2ISSN$$a1932-2259
000286719 0247_ $$2ISSN$$a1932-2267
000286719 0247_ $$2altmetric$$aaltmetric:158154236
000286719 037__ $$aDKFZ-2024-00059
000286719 041__ $$aEnglish
000286719 082__ $$a610
000286719 1001_ $$0P:(DE-He78)502ae8d7e251904ee3374b7a6d7accd7$$aGüven, Deniz Can$$b0$$eFirst author
000286719 245__ $$aSurvivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review.
000286719 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2025
000286719 3367_ $$2DRIVER$$aarticle
000286719 3367_ $$2DataCite$$aOutput Types/Journal article
000286719 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747308126_1549$$xReview Article
000286719 3367_ $$2BibTeX$$aARTICLE
000286719 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286719 3367_ $$00$$2EndNote$$aJournal Article
000286719 500__ $$aEA:C071#EA:C070#LA:C071#LA:C070# / Volume 19, pages 806–845, (2025)
000286719 520__ $$aImmune checkpoint inhibitors (ICIs) have become a central part of cancer care. However, the survivorship outcomes in patients treated with ICIs are understudied. Therefore, we conducted a scoping review to evaluate the current status of the field and to establish research gaps regarding survivorship outcomes with ICIs in real-life cohorts.We used the Web of Science, PubMed, and Embase databases to systematically filter published studies with real-life cohorts from January 1, 2010, until October 19, 2022. Studies evaluating at least one survivorship outcome in ICI-treated patients were included.A total of 39 papers were included. Quality of life (QoL) (n = 23), toxicity burden (n = 16), and psychosocial issues (n = 9) were the most frequently evaluated survivorship outcomes. Anti-PD-1/PD-L1 monotherapy and a response to treatment were associated with better QoL. In addition, the ICIs were associated with grade 3 or higher immune-related adverse events (irAEs) in 10-15% and late/long-term irAEs in 20-30% of the survivors. Regarding psychosocial problems, over 30% of survivors showed evidence of anxiety and depression, and 30-40% of survivors reported neurocognitive impairments.The survivors treated with ICIs have impairments in most survivorship domains. Further research is needed to gather data on the understudied survivorship outcomes like late and long-term effects, fertility, financial toxicity, and return to work in survivors treated with ICIs.Available evidence demonstrates that a significant portion of survivors treated with ICIs have a significant toxicity burden, lower QoL than the general population, and a high rate of psychosocial problems.
000286719 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286719 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286719 650_7 $$2Other$$aImmune checkpoint inhibitor
000286719 650_7 $$2Other$$aImmune-related adverse event
000286719 650_7 $$2Other$$aImmunotherapy
000286719 650_7 $$2Other$$aQuality of life
000286719 650_7 $$2Other$$aSurvivorship
000286719 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa Sy$$b1$$udkfz
000286719 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b2$$eLast author$$udkfz
000286719 773__ $$0PERI:(DE-600)2388888-X$$a10.1007/s11764-023-01507-w$$p806–845$$tJournal of cancer survivorship$$v19$$x1932-2259$$y2025
000286719 8564_ $$uhttps://inrepo02.dkfz.de/record/286719/files/s11764-023-01507-w.pdf$$yRestricted
000286719 8564_ $$uhttps://inrepo02.dkfz.de/record/286719/files/s11764-023-01507-w.pdf?subformat=pdfa$$xpdfa$$yRestricted
000286719 8767_ $$8SN-2024-02123-c$$92025-09-09$$d2025-10-01$$eHybrid-OA$$jZahlung erfolgt
000286719 909CO $$ooai:inrepo02.dkfz.de:286719$$pVDB$$pOpenAPC$$popenCost
000286719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)502ae8d7e251904ee3374b7a6d7accd7$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000286719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000286719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000286719 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286719 9141_ $$y2024
000286719 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-25$$wger
000286719 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-25$$wger
000286719 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER SURVIV : 2022$$d2023-08-25
000286719 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000286719 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000286719 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000286719 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000286719 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x1
000286719 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000286719 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x1
000286719 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000286719 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x1
000286719 980__ $$ajournal
000286719 980__ $$aVDB
000286719 980__ $$aI:(DE-He78)C071-20160331
000286719 980__ $$aI:(DE-He78)C070-20160331
000286719 980__ $$aUNRESTRICTED
000286719 980__ $$aAPC